Literature DB >> 22595755

The role of autophagy in the pathogenesis of glycogen storage disease type II (GSDII).

A C Nascimbeni1, M Fanin, E Masiero, C Angelini, M Sandri.   

Abstract

Regulated removal of proteins and organelles by autophagy-lysosome system is critical for muscle homeostasis. Excessive activation of autophagy-dependent degradation contributes to muscle atrophy and cachexia. Conversely, inhibition of autophagy causes accumulation of protein aggregates and abnormal organelles, leading to myofiber degeneration and myopathy. Defects in lysosomal function result in severe muscle disorders such as Pompe (glycogen storage disease type II (GSDII)) disease, characterized by an accumulation of autophagosomes. However, whether autophagy is detrimental or not in muscle function of Pompe patients is unclear. We studied infantile and late-onset GSDII patients and correlated impairment of autophagy with muscle wasting. We also monitored autophagy in patients who received recombinant α-glucosidase. Our data show that infantile and late-onset patients have different levels of autophagic flux, accumulation of p62-positive protein aggregates and expression of atrophy-related genes. Although the infantile patients show impaired autophagic function, the late-onset patients display an interesting correlation among autophagy impairment, atrophy and disease progression. Moreover, reactivation of autophagy in vitro contributes to acid α-glucosidase maturation in both healthy and diseased myotubes. Together, our data suggest that autophagy protects myofibers from disease progression and atrophy in late-onset patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22595755      PMCID: PMC3438501          DOI: 10.1038/cdd.2012.52

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  20 in total

1.  FoxO3 controls autophagy in skeletal muscle in vivo.

Authors:  Cristina Mammucari; Giulia Milan; Vanina Romanello; Eva Masiero; Ruediger Rudolf; Paola Del Piccolo; Steven J Burden; Raffaella Di Lisi; Claudia Sandri; Jinghui Zhao; Alfred L Goldberg; Stefano Schiaffino; Marco Sandri
Journal:  Cell Metab       Date:  2007-12       Impact factor: 27.287

2.  Inhibition of lysosomal function in red and white skeletal muscles by chloroquine.

Authors:  W T Stauber; A M Hedge; J J Trout; B A Schottelius
Journal:  Exp Neurol       Date:  1981-02       Impact factor: 5.330

3.  Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease).

Authors:  I Nishino; J Fu; K Tanji; T Yamada; S Shimojo; T Koori; M Mora; J E Riggs; S J Oh; Y Koga; C M Sue; A Yamamoto; N Murakami; S Shanske; E Byrne; E Bonilla; I Nonaka; S DiMauro; M Hirano
Journal:  Nature       Date:  2000-08-24       Impact factor: 49.962

4.  Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency.

Authors:  Anna Chiara Nascimbeni; Marina Fanin; Elisabetta Tasca; Corrado Angelini
Journal:  Neurology       Date:  2008-02-19       Impact factor: 9.910

5.  Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.

Authors:  Marco Sandri; Claudia Sandri; Alex Gilbert; Carsten Skurk; Elisa Calabria; Anne Picard; Kenneth Walsh; Stefano Schiaffino; Stewart H Lecker; Alfred L Goldberg
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

6.  Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand...

Authors:  Nina Raben; Shoichi Takikita; Maria G Pittis; Bruno Bembi; Suely K N Marie; Ashley Roberts; Laura Page; Priya S Kishnani; Benedikt G H Schoser; Yin-Hsiu Chien; Evelyn Ralston; Kanneboyina Nagaraju; Paul H Plotz
Journal:  Autophagy       Date:  2007-06-15       Impact factor: 16.016

7.  Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression.

Authors:  Stewart H Lecker; R Thomas Jagoe; Alexander Gilbert; Marcelo Gomes; Vickie Baracos; James Bailey; S Russ Price; William E Mitch; Alfred L Goldberg
Journal:  FASEB J       Date:  2004-01       Impact factor: 5.191

8.  X-linked myopathy with excessive autophagy: a new hereditary muscle disease.

Authors:  H Kalimo; M L Savontaus; H Lang; L Paljärvi; V Sonninen; P B Dean; K Katevuo; A Salminen
Journal:  Ann Neurol       Date:  1988-03       Impact factor: 10.422

9.  Human skeletal muscle atrophy in amyotrophic lateral sclerosis reveals a reduction in Akt and an increase in atrogin-1.

Authors:  Bertrand Léger; Lodovica Vergani; Gianni Sorarù; Peter Hespel; Wim Derave; Charles Gobelet; Carla D'Ascenzio; Corrado Angelini; Aaron P Russell
Journal:  FASEB J       Date:  2006-01-17       Impact factor: 5.191

10.  Fiber type conversion by PGC-1α activates lysosomal and autophagosomal biogenesis in both unaffected and Pompe skeletal muscle.

Authors:  Shoichi Takikita; Cynthia Schreiner; Rebecca Baum; Tao Xie; Evelyn Ralston; Paul H Plotz; Nina Raben
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

View more
  49 in total

1.  Therapeutic advances in the management of Pompe disease and other metabolic myopathies.

Authors:  Corrado Angelini; Anna Chiara Nascimbeni; Claudio Semplicini
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

2.  Salmeterol with Liver Depot Gene Therapy Enhances the Skeletal Muscle Response in Murine Pompe Disease.

Authors:  Sang-Oh Han; Songtao Li; Jeffrey I Everitt; Dwight D Koeberl
Journal:  Hum Gene Ther       Date:  2019-04-05       Impact factor: 5.695

3.  Autophagy in Natural History and After ERT in Glycogenosis Type II.

Authors:  Corrado Angelini; Anna C Nascimbeni; Marina Fanin
Journal:  JIMD Rep       Date:  2015-02-25

4.  Therapeutic Benefit of Autophagy Modulation in Pompe Disease.

Authors:  Jeong-A Lim; Baodong Sun; Rosa Puertollano; Nina Raben
Journal:  Mol Ther       Date:  2018-05-03       Impact factor: 11.454

Review 5.  Molecular regulation of autophagy and its implications for metabolic diseases.

Authors:  Stefan W Ryter; Ja Kun Koo; Augustine M K Choi
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2014-07       Impact factor: 4.294

6.  Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase.

Authors:  Francesco Puzzo; Pasqualina Colella; Maria G Biferi; Deeksha Bali; Nicole K Paulk; Patrice Vidal; Fanny Collaud; Marcelo Simon-Sola; Severine Charles; Romain Hardet; Christian Leborgne; Amine Meliani; Mathilde Cohen-Tannoudji; Stephanie Astord; Bernard Gjata; Pauline Sellier; Laetitia van Wittenberghe; Alban Vignaud; Florence Boisgerault; Martine Barkats; Pascal Laforet; Mark A Kay; Dwight D Koeberl; Giuseppe Ronzitti; Federico Mingozzi
Journal:  Sci Transl Med       Date:  2017-11-29       Impact factor: 17.956

7.  Basal autophagy is required for the efficient catabolism of sialyloligosaccharides.

Authors:  Junichi Seino; Li Wang; Yoichiro Harada; Chengcheng Huang; Kumiko Ishii; Noboru Mizushima; Tadashi Suzuki
Journal:  J Biol Chem       Date:  2013-07-23       Impact factor: 5.157

Review 8.  Engineered skeletal muscles for disease modeling and drug discovery.

Authors:  Jason Wang; Alastair Khodabukus; Lingjun Rao; Keith Vandusen; Nadia Abutaleb; Nenad Bursac
Journal:  Biomaterials       Date:  2019-08-08       Impact factor: 12.479

Review 9.  Restoring the regenerative balance in neuromuscular disorders: satellite cell activation as therapeutic target in Pompe disease.

Authors:  Gerben J Schaaf; Rodrigo Canibano-Fraile; Tom J M van Gestel; Ans T van der Ploeg; W W M Pim Pijnappel
Journal:  Ann Transl Med       Date:  2019-07

10.  Pompe disease results in a Golgi-based glycosylation deficit in human induced pluripotent stem cell-derived cardiomyocytes.

Authors:  Kunil K Raval; Ran Tao; Brent E White; Willem J De Lange; Chad H Koonce; Junying Yu; Priya S Kishnani; James A Thomson; Deane F Mosher; John C Ralphe; Timothy J Kamp
Journal:  J Biol Chem       Date:  2014-12-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.